Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

References

• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Leuk Res 2012;36(12):1481-9
   Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 2007;13:366-71
   Google Scholar
• Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-3
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008;22:1299-307
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 2009;94:7-10
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009;37:1016-21
   PubMed Web of Science ®Google Scholar
• Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88(6):507-16
   PubMedGoogle Scholar
• Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-83
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756-61
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-9
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356(5):459-68
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6
   PubMed Web of Science ®Google Scholar
• Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112(1):141-9
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112(3):844-7
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23(5):905-11
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360(22):2289-301
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012;26(5):1053-64
   Google Scholar
• Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012;5:12
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24(7):1302-9
   PubMed Web of Science ®Google Scholar
• Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26(3):475-80
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Bain BJ, Thiele J, et al. Myeloproliferative neoplasm, unclassifiable. In: Campo E, Swerdlow SH, Harris NL et al. editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 64-5
   Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51
   PubMed Web of Science ®Google Scholar
• Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7
   PubMed Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88(2):141-50
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Orazi A, et al. Polycythaemia vera. In: Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 40-3
   Google Scholar
• Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-9
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005;20:317-28
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Bone marrow features of diagnostic impact in erythrocytosis. Ann Hematol 2005;84:362-7
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Zankovich R, et al. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001;86:368-74
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-32
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;119(10):2239-41
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post–polycythemia vera and post–essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-8
   PubMed Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 44-7
   Google Scholar
• Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008;111:1862-5
   PubMed Web of Science ®Google Scholar
• Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosid allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2012;25:1193-202
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011;117:5857-9
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Orazi A, et al. Essential thrombocythemia. In: Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008. p. 48-50
   Google Scholar
• Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010;85(1):62-9
   PubMed Web of Science ®Google Scholar
• Thiele J. Philadelphia chromosome-negative chronic myeloproliferative disease. Am J Clin Pathol 2009;132:261-80
   PubMed Web of Science ®Google Scholar
• Briere JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 2006;32:208-18
   PubMedGoogle Scholar
• Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130:2031-8
   PubMed Web of Science ®Google Scholar
• Smalberg JH, Murad SD, Braakman E, et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006;91:1712-13
   PubMedGoogle Scholar
• De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-14
   PubMedGoogle Scholar
• McMahon C, Abu-Elmagd K, Bontempo FA, et al. JAK2 V617F mutation in patients with catastrophic intra-abdominal thrombosis. Am J Clin Pathol 2007;127:736-43
   Google Scholar
• Regina S, Herault O, D’Alteroche L, et al. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859-61
   Google Scholar
• Finazzi G, De Stefano V, Barbui T. Are MPNs vascular diseases? Curr Hematol Malig Rep 2013;8(4):307-16
   Google Scholar
• Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122(13):2176-84
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Commandeur S, Hoogenboom GJ, et al. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007;86:793-800
   Google Scholar
• Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006;44:1528-34
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005;113:213-19
   PubMed Web of Science ®Google Scholar
• Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the ‘‘early’’ prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008;130:336-42
   PubMedGoogle Scholar
• Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia Vera (mPV): results of an international study. Am J Hematol 2013. [Epub ahead of print]
   Google Scholar
• Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012;120(3):569-71
   Web of Science ®Google Scholar
• Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012;26(4):716-19
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013;27(10):1953-8
   Google Scholar
• Brousseau M, Parot-Schinkel E, Moles MP, et al. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010;56:758-67
   PubMed Web of Science ®Google Scholar
• Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012;7:e35631
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1104 patients. J Clin Oncol 2011;29(23):3179-84
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Personalized management of essential thrombocythemia – application of recent evidence to clinical practice. Leukemia 2013;27(8):1617-20
   Google Scholar
• Carobbio A, Finazzi G, Thiele J, et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012;87(2):203-4
   Google Scholar
• Hussein K, Bock O, Theophile K, et al. JAK2 (V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009;37:1186-1193.e7
   Google Scholar
• Thiele J, Kvasnicka HM, Zankovich R, et al. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85:1126-34
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 2005;32:380-94
   PubMed Web of Science ®Google Scholar
• Florena AM, Tripodo C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89:911-19
   PubMed Web of Science ®Google Scholar
• Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006;47:1774-81
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645-51
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009;27:e220-1; author reply e222-3
   Google Scholar
• Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008;111(1):60-70
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009;27(18):2991-9
   PubMed Web of Science ®Google Scholar
• Buhr T, Hebeda K, Kaloutsi V, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5
   PubMed Web of Science ®Google Scholar
• Gianelli U, Bossi A, Cortinovis I, et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol 2013. [Epub ahead of print]
   Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
   PubMed Web of Science ®Google Scholar
• Tefferi A, Litzow M, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365(15):1455-7
   PubMed Web of Science ®Google Scholar
• Harrison C, Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol 2012;3(6):341-54
   PubMedGoogle Scholar
• Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013;31(10):1285-92
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
   PubMed Web of Science ®Google Scholar
• Kvasnicka H, Thiele J, Bueso-Ramos CE, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. Haematologica 2013;(98 Suppl 2):Abstract S591
   Google Scholar
• Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2013. [Epub ahead of print]
   Google Scholar